Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...

BioMarin Pharmaceutical (BMRN ... A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock ...

monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy, or in combination with chemotherapy or cabozantinib. In the past 30 days, estimates for BioMarin ...

Current treatment options are a haematopoietic stem cell transplant (HSCT) – a risky procedure that has to be done before the age of two – or weekly infusions with BioMarin's enzyme ...

BioMarin Pharmaceutical Inc. has a one year low of $60.63 and a one year high of $94.85. The company has a market capitalization of $12.55 billion, a P/E ratio of 39.44, a price-to-earnings-growth ...

BioMarin Pharmaceutical has a twelve month low of $60.63 and a twelve month high of $94.85. The company has a market capitalization of $12.55 billion, a price-to-earnings ratio of 39.44, a PEG ...

In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended December 2024. While this widely-known ...